| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Sealbond Ltd | Director, Other*, 10%+ Owner | 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG | /s/ Wong Wun Lam, Director of Sealbond Limited | 25 Nov 2025 | 0002040446 |
| Conjoint Inc. | Director, Other*, 10%+ Owner | 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG | /s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc. | 25 Nov 2025 | 0002061651 |
| CK Life Sciences Intl (Holdings) Inc | Director, Other*, 10%+ Owner | 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG | /s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc. | 25 Nov 2025 | 0001297567 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DWTX | Common Stock | Conversion of derivative security | +21,610,950 | +10224% | 21,822,333 | 21 Nov 2025 | Direct | F1, F2 | ||
| transaction | DWTX | Common Stock | Conversion of derivative security | +2,842,638 | 2,842,638 | 21 Nov 2025 | By Conjoint Inc. | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DWTX | Series A Preferred Stock | Conversion of derivative security | $0 | -2,161 | -100% | $0.000000 | 0 | 21 Nov 2025 | Common Stock | 21,610,950 | Direct | F1, F2, F4 | |
| transaction | DWTX | Series A-1 Preferred Stock | Conversion of derivative security | $0 | -284 | -100% | $0.000000 | 0 | 21 Nov 2025 | Common Stock | 2,842,638 | By Conjoint Inc. | F1, F3 |
| Id | Content |
|---|---|
| F1 | On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date. |
| F2 | Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose. |
| F3 | Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose. |
| F4 | Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended. |
Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.